Quality Improvement Grant Request for Proposals: Optimizing Maternal RSV Immunization Delivery
Pfizer Inc.'s Quality Improvement Grant funds projects using evidence-based strategies to enhance maternal RSV immunization delivery and address disparities in prenatal care.
Funder: Pfizer Inc.
Due Dates: September 10, 2026 (full proposal, 23:59 EST)
Funding Amounts: $100,000–$200,000 per project; up to $200,000 total; max 18 months duration
Summary: Supports quality improvement initiatives to optimize maternal RSV immunization delivery, focusing on access, equity, care coordination, and measurable improvements in prenatal care.
Key Information: Not for clinical research; projects must address system/practice change and demonstrate measurable outcomes.
Description
This grant, funded by Pfizer Inc. in partnership with the Society for Maternal-Fetal Medicine (SMFM), supports independent quality improvement (QI) initiatives aimed at optimizing the delivery of maternal immunization, with a specific focus on Respiratory Syncytial Virus (RSV) vaccination during pregnancy. The program seeks projects that implement evidence-based, measurable interventions to improve real-world delivery of maternal RSV immunization across diverse healthcare systems. Emphasis is placed on improving access, provider–patient communication, care coordination, and addressing both structural and behavioral barriers to vaccine uptake and equity—especially in communities disproportionately affected by vaccine-preventable diseases and maternal care deserts. Multidisciplinary, collaborative approaches leveraging data-driven QI methodologies and fostering the integration of maternal immunization into routine prenatal care are encouraged.
